Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2026
Fixed Triple-Combination Bimatoprost/Brimonidine/Timolol Versus Separate Administration in Glaucoma: Randomized Clinical Trial.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Machado Lilian F, Kawamuro Mariana, Bando André, Sokabe Lucca, Parmigiani Luana, Wada Giovanna, Yuji Abe Ricardo, Prata Tiago S, Teixeira Sérgio H, Paranhos Augusto, Gracitelli Carolina P B
Аннотация
PURPOSE: To compare the efficacy, tolerability, and persistence of a fixed triple combination (FTC) of bimatoprost 0.01%/brimonidine tartrate 0.15%/timolol maleate 0.5% with the same agents administered separately. Secondary outcomes included adverse effects, quality of life (QoL), and adherence.
METHODS: This randomized clinical trial included 46 patients with primary open-angle (n = 36) or primary angle-closure glaucoma (n = 10) requiring three or more hypotensive agents. After a washout period, participants were randomized to FTC twice daily or to bimatoprost 0.03% once, brimonidine 0.2%, and timolol 0.5% twice daily. Examinations at 1, 4, and 6 months included conjunctival hyperemia grading, tear break-up time, corneal staining, and validated questionnaires assessing QoL, ocular surface, and adherence.
RESULTS: Mean age was 65.0 ± 11.5 years; baseline mean deviation -11.94 ± 8.72 dB, and prior treatment 3.9 ± 2.5 years. Both regimens significantly reduced intraocular pressure (FTC group: 24.37 ± 5.92 to 15.42 ± 2.69 mmHg; unfixed group: 26.18 ± 6.79 to 14.53 ± 3.49 mmHg; P < 0.001), with no difference between groups. Hyperemia worsened (P = 0.009), QoL declined (P < 0.001), and adherence remained stable. Discontinuation reached 63%, mainly from disease progression (34.5%) and intolerance (27.6%). Survival analysis showed a 69.6% probability of treatment maintenance at 6 months. Among completers, 61.8% had worsening hyperemia (P = 0.004), whereas discontinuers exhibited QoL decline (P < 0.001). In FTC, the visual field deteriorated in the discontinued group (Δ-1.11; P = 0.025).
CONCLUSIONS: Both regimens achieved similar efficacy but were associated with progressive hyperemia, reduced QoL, and low persistence, underscoring the limitations of multiple topical glaucoma therapy.
METHODS: This randomized clinical trial included 46 patients with primary open-angle (n = 36) or primary angle-closure glaucoma (n = 10) requiring three or more hypotensive agents. After a washout period, participants were randomized to FTC twice daily or to bimatoprost 0.03% once, brimonidine 0.2%, and timolol 0.5% twice daily. Examinations at 1, 4, and 6 months included conjunctival hyperemia grading, tear break-up time, corneal staining, and validated questionnaires assessing QoL, ocular surface, and adherence.
RESULTS: Mean age was 65.0 ± 11.5 years; baseline mean deviation -11.94 ± 8.72 dB, and prior treatment 3.9 ± 2.5 years. Both regimens significantly reduced intraocular pressure (FTC group: 24.37 ± 5.92 to 15.42 ± 2.69 mmHg; unfixed group: 26.18 ± 6.79 to 14.53 ± 3.49 mmHg; P < 0.001), with no difference between groups. Hyperemia worsened (P = 0.009), QoL declined (P < 0.001), and adherence remained stable. Discontinuation reached 63%, mainly from disease progression (34.5%) and intolerance (27.6%). Survival analysis showed a 69.6% probability of treatment maintenance at 6 months. Among completers, 61.8% had worsening hyperemia (P = 0.004), whereas discontinuers exhibited QoL decline (P < 0.001). In FTC, the visual field deteriorated in the discontinued group (Δ-1.11; P = 0.025).
CONCLUSIONS: Both regimens achieved similar efficacy but were associated with progressive hyperemia, reduced QoL, and low persistence, underscoring the limitations of multiple topical glaucoma therapy.